Rate My Professor Logan Walker

Walker's research centers on understanding the impact of genetic changes on health, with a focus on cancer genetics, including breast, ovarian, and endometrial cancers. He leads the New Zealand Familial Breast Cancer Study, contributing to international consortia such as the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA), Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), and Endometrial Cancer Association Consortium (ECAC). As a member of multiple ClinGen working groups and expert panels, including those for hereditary breast, ovarian, and pancreatic cancers, he has co-developed international guidelines for RNA-based genetic testing and ACMG/AMP variant classification in BRCA1 and BRCA2 genes. His leadership in multi-site studies has identified germline copy number variants associated with cancer risk. Key publications include 'BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes' (2025, American Journal of Human Genetics), 'Germline copy number variants and endometrial cancer risk' (2024, Human Genetics), and 'Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel' (2024, American Journal of Human Genetics). Walker delivered his Inaugural Professorial Lecture, 'Preparing for the future of genetic health,' in March 2025.